Skip to main content
. 2016 Jul 25;12(3):2175–2180. doi: 10.3892/ol.2016.4912

Figure 1.

Figure 1.

In vitro effects of azacytidine and/or LBH589 on (A) miRNA-124, (B) CDK4, (C) CDK6 and (D) EZH2 mRNA expression in HL60 cells. *P<0.05 vs. Control (n=3). The P-values obtained were as follows: (A) P=0.620, 0.740 and 0.032 for AZA, LBH and LBA, respectively, vs. Control; (B) P=0.812, 0.511 and 0.025 for AZA, LBH and LBA, respectively, vs. Control; (C) P=0.519, 0.024 and 0.031 for AZA, LBH and LBA, respectively, vs. Control; and (D) P=0.025, 0.002 and 0.008 for AZA, LBH and LBA, respectively, vs. Control. LBH589, panobinostat; miRNA, microRNA; CDK, cyclin-dependent kinase; EZH2, enhancer of zeste homolog 2; AZA, cells treated with 1.0 µM 5-azacytidine for 48 h; LBH, cells treated with 20 nM LBH589 for 48 h; LBA, cells treated with 20 nM LBH589 + 1.0 µM AZA; Control, HL60 cells without treatment.